On November 24, 2020 the Spanish start-up, specialized in developing a technology to transport drugs to the brain, reported the company is seeking up to three million euros to reach the clinical trial (Press release, Gate2Brain, NOV 24, 2020, View Source [SID1234641077]). The CEO of Gate2Brain, Meritxell Teixidó, explains to PlantaDoce that the company plans to open a financing round in April 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The start-up develops a technology to transport drugs to the brain . The company will use the funds to advance therapeutic tests since, although it has identified the drug to deliver to this organ according to the group of pediatric brain tumors, it must improve transport.

In this way, the company would increase the effectiveness of brain disease treatments with its technology, while reducing side effects. Teixidó assures that the objective is "to validate the platform and for a pharmaceutical company to look at it to acquire the company . "

Gate2Brain seeks to improve the effectiveness of brain disease treatments

The company is a spin off of the Barcelona Biomedical Research Institute, the University of Barcelona (UB) and the Sant Joan de Déu Research Institute of the Sant Joan de Déu Hospital (SJD). The company has its headquarters in the Barcelona Science Park.

Gate2Brain envisions its technology will allow drugmakers to recover promising drugs that don’t make it to market because they can’t be transported to the brain. The company’s CEO states that "98% of drug candidates are discarded because they do not pass the barrier and our technology would allow investment in these drugs not to be left in a corner." The company is in contact with some pharmaceutical companies .

The start-up plans to open a financing round of between two million euros and three million euros in April 2021 . Gate2Brain estimates to begin the clinical trial in 2023. The company has carried out some tests at the Sant Joan de Déu Hospital in Barcelona and has observed that its technology would have applicability in various tumors.

Gate2Brain has received funding from the Botín Foundation

Gate2Brain has received support from the Botín Foundation’s Mind The Gap Program, which invests up to half a million euros per project . The start-up obtained online research support from the CaixaImpulse program of the La Caixa Foundation and funding from the Agency for Management and University Research Grants (Agaur) in the Knowledge Industry Grants call.

The company currently has five workers. Gate2Brain, founded by Teixidó and three other entrepreneurs, has Marc Ramis, CEO of Ninevah Therapeutics, as an advisor. The founders control the majority of the company’s shareholders.

On November 24, 2020 InDex Pharmaceuticals Holding AB (publ) reported that CEO Peter Zerhouni will present the company at Redeye Life Science Day at 13:50 CET on November 26 (Press release, InDex Pharmaceuticals, NOV 24, 2020, View Source [SID1234571648]). The presentation will be livestreamed and can be followed at View Source, where the presentation also will be available afterwards.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will also be available afterwards on the company’s page in Redeye Universe (www.redeye.se/company/index-pharmaceuticals) and on the company’s website (www.indexpharma.com).

On November 24, 2020 Kadmon Holdings, Inc. (NASDAQ:KDMN) reported that the Company will host a virtual key opinion leader event on Sunday, December 6, 2020 at 11:15 a.m. PT (2:15 p.m. ET) at the 62nd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting (Press release, Kadmon, NOV 24, 2020, View Source [SID1234571670]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the previously announced oral presentation of 12-month data from ROCKstar (KD025-213), the ongoing pivotal trial of belumosudil (KD025) for the treatment of chronic graft-versus-host disease (cGVHD), Corey Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute, will contextualize the data across the Company’s recent New Drug Application (NDA) filing and discuss how belumosudil may fit into the cGVHD treatment landscape, if approved.

The live webcast of the event will be accessible from the Investors page of Kadmon’s website, investors.kadmon.com. Details of the ASH (Free ASH Whitepaper) oral presentation and related key opinion leader event are as follows:

ROCKstar (KD025-213) Oral Presentation

Title: Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The ROCKstar Study (KD025-213)
Presenter: Corey Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune
Date & Time: Sunday, December 6, 2020, 9:30 a.m. – 11:00 a.m. PT (12:30 p.m. – 2:00 p.m. ET)
Abstract #: 353

The accepted abstract is now available online at www.hematology.org. The oral presentation will include updated data not available in the abstract.

Key Opinion Leader Event Details

The key opinion leader event will take place on Sunday, December 6, 2020 at 2:15 p.m. ET and will feature the presenting author of the ASH (Free ASH Whitepaper) presentation, Corey Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute. The live webcast event may be accessed through the following link:

Title: Kadmon Key Opinion Leader Event
Speaker: Corey Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
Date & Time: Sunday, December 6, 2020, 11:15 a.m. – 12:00 p.m. PT (2:15 p.m. – 3:00 p.m. ET)
Webcast Link: View Source
Webinar ID: 980 1644 8979

Individuals may participate in an interactive Q&A session by submitting questions via the webcast platform. The live webcast may also be accessed through the Events & Presentations page in the Investors section of the Company’s website at investors.kadmon.com. An archived version of the webcast will be available in the News & Events section of the Investors page of Kadmon’s website for 60 days following the event.

About ROCKstar

ROCKstar (KD025-213) is an ongoing open-label trial of belumosudil in patients with cGVHD who have received at least two prior lines of systemic therapy. Patients were randomized to receive belumosudil 200 mg once daily or 200 mg twice daily, enrolling 66 patients per arm. The primary endpoint of the study is Overall Response Rate (ORR). The ORR endpoint was met at the interim analysis, conducted two months after completion of enrollment. At the study’s primary analysis, conducted six months after completion of enrollment, belumosudil achieved ORRs of 73% and 74% in the respective arms. Belumosudil has been well tolerated and adverse events have been consistent with those expected in the patient population.

About Belumosudil

Belumosudil (KD025) is a selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a signaling pathway that modulates inflammatory response and pro-fibrotic processes. Kadmon has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for belumosudil for the treatment of patients with cGVHD and the NDA is being reviewed under the FDA’s Real-Time Oncology Review (RTOR) pilot program. The FDA has granted Breakthrough Therapy Designation to belumosudil for the treatment of patients with cGVHD after failure of two or more lines of systemic therapy. The FDA has also granted Orphan Drug Designation to belumosudil for the treatment of cGVHD.

About cGVHD

cGVHD is a common and often fatal complication following hematopoietic stem cell transplantation. In cGVHD, transplanted immune cells (graft) attack the patient’s cells (host), leading to inflammation and fibrosis in multiple tissues, including skin, mouth, eye, joints, liver, lung, esophagus and gastrointestinal tract. Approximately 14,000 patients in the United States are currently living with cGVHD.

On November 24, 2020 Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, reported that D. Keith Grossman, Nevro’s Chairman, CEO and President will participate in Citi Bank’s Head Shoulders Knees and Toes Conference Call Series on November 30, 2020 at 2pm ET (Press release, Nevro, NOV 24, 2020, View Source [SID1234571693]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors interested in listening to the call may do so by dialing (856) 344-9142 in the U.S., using Conference ID: 3168278. This dial-in information is available on the "Investors" section of the Company’s website at: www.nevro.com.

On November 24, 2020 PreGene, a Shenzhen biotech, reported that it closed a $21 million B financing as it looks forward to an IPO on the Hong Kong exchange. The funding was led by Haier Biomedical (Press release, PreGene, NOV 24, 2020, View Source [SID1234571741]). PreGene claims to have the world’s only fusion drug and nano-antibody drug biotechnology R&D platform. Founded in 2012, PreGene is also developing TCR-T, CAR-T and stem cell candidates. Its BCMA CAR-T candidate is approved to start clinical trials in China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!